A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

Claire L. Mitchell (1) , J. P. B. O'Connor (1, 2, 3) , C. Roberts (2, 3) , Y. Watson (2, 3) , A. Jackson (2, 3) , S. Cheung (2, 3) , J. Evans (4) , J. Spicer (5) , A. Harris (6) , C. Kelly (4) , S. Rudman (5) , M. Middleton (6) , A. Fielding (7) , J. Tessier (7) , H. Young (7) , G. J. M. Parker (2, 3) , G. C. Jayson (1, 3)

1 Department of Medical Oncology
2 Imaging Science and Biomedical Engineering, School of Cancer and Imaging Sciences
3 The University of Manchester Biomedical Imaging Institute
4 Beatson West of Scotland Cancer Centre
5 King‘s College London
6 CRUK Medical Oncology Unit
7 AstraZeneca

Mots clés: Cediranib; CT enhancement; DCE-MRI; Food; Pharmacodynamics; Pharmacokinetics

Claire L. Mitchell, J. P. B. O'Connor, C. Roberts, Y. Watson, A. Jackson, et al.. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemotherapy and Pharmacology, 2010, 68 (3), pp.631-641. ⟨10.1007/s00280-010-1534-3⟩. ⟨hal-00646938⟩